Sook-Bin Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sook-Bin Woo has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Glenn J. Hanna
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
5 shared publications - Ana Babic
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
4 shared publications - Ann H. Partridge
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
4 shared publications - Bicky Thapa
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215-5450, USA Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
4 shared publications - Brian D. Crompton
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
4 shared publications - Catherine R. Marinac
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 8 December 2023
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (9) , 788-792
Gingival pigmentation in a 15-year-old female patient
- 8 December 2023
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (9) , 788-792
Gingival pigmentation in a 15-year-old female patient
- 19 February 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 35 (8) , 1034-1044
Characterization of initial/early histologic features of proliferative leukoplakia and correlation with malignant transformation: a multicenter study
- 19 February 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 35 (8) , 1034-1044
Characterization of initial/early histologic features of proliferative leukoplakia and correlation with malignant transformation: a multicenter study
- 1 November 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (5) , e186-e189
Calcifying synovial sarcoma of the tongue with SS18 rearrangement: a rare variant in a rare location
- 1 November 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (5) , e186-e189
Calcifying synovial sarcoma of the tongue with SS18 rearrangement: a rare variant in a rare location
- 1 August 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (2) , 210-216
Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients
- 1 August 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (2) , 210-216
Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients
- 1 February 2020
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 129 (2) , 120-124
Burning mouth syndrome: a diagnostic challenge
- 1 February 2020
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 129 (2) , 120-124
Burning mouth syndrome: a diagnostic challenge
- Top Cited Papers
- 18 March 2019
- Published by Springer Nature in Head and Neck Pathology
- Vol. 13 (3) , 423-439
Oral Epithelial Dysplasia and Premalignancy
Leukoplakia and erythroplakia are two entities under the moniker of “oral potentially malignant disorders” that are highly associated with the presence of oral epithelial dysplasia (OED) at first biopsy, while lesions of submucous fibrosis develop OED after being present for years. Importantly, traumatic/frictional keratoses are often mistaken clinically for leukoplakia and it is important for the pathologist to recognize and report them as such. The features of OED have been well-described and other architectural features will be discussed here, in particular verrucous and papillary architecture, bulky epithelial proliferation and epithelial atrophy. Proliferative leukoplakia, verrucous or otherwise, often show only hyperkeratosis in early lesions, with development of OED occurring over time, and squamous cell carcinoma developing in the majority of cases over time. The concept of hyperkeratosis without features of OED and that is not reactive, is likely a precursor to the dysplastic phenotype. Many cases of leukoplakia exhibiting OED are associated with a band of lymphocytes at the interface and these should not be mistaken for oral lichen planus.
- 18 March 2019
- Published by Springer Nature in Head and Neck Pathology
- Vol. 13 (3) , 423-439
Top Cited PapersOral Epithelial Dysplasia and Premalignancy
Leukoplakia and erythroplakia are two entities under the moniker of “oral potentially malignant disorders” that are highly associated with the presence of oral epithelial dysplasia (OED) at first biopsy, while lesions of submucous fibrosis develop OED after being present for years. Importantly, traumatic/frictional keratoses are often mistaken clinically for leukoplakia and it is important for the pathologist to recognize and report them as such. The features of OED have been well-described and other architectural features will be discussed here, in particular verrucous and papillary architecture, bulky epithelial proliferation and epithelial atrophy. Proliferative leukoplakia, verrucous or otherwise, often show only hyperkeratosis in early lesions, with development of OED occurring over time, and squamous cell carcinoma developing in the majority of cases over time. The concept of hyperkeratosis without features of OED and that is not reactive, is likely a precursor to the dysplastic phenotype. Many cases of leukoplakia exhibiting OED are associated with a band of lymphocytes at the interface and these should not be mistaken for oral lichen planus.